drugset
drugset / Trial / NCT03227198

IMMNC-HF: IntraMyocardial Injection of Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients

NCT03227198 ↗

Phase 1/2 Unknown 5 enrolled SCARM Institute, Tabriz, Iran
Non-randomizedParallel-groupDouble-blindTreatment

Summary

This is a prospective, randomised double blind, controlled, parallel-group phase I and II study. Its aim is to assess the Evaluation of the intramyocardial injection of autologous bone marrow derived mononuclear stem cells is safe and effective in hear failure patients with reduced left ventricular ejection fraction(\<=30%) when compared to a control group of patients undergoing best medical care.

Timeline

Start
2020-10-14
Primary completion
2021-08-10
Completion
2021-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous bone marrow-derived mononuclear cells Cell therapy — Other

Indications

heart failure